长链非编码RNA与肾癌靶向药物耐药

发布时间：2018-05-01 18:10

本文选题：肾肿瘤 + 靶向治疗　；参考：《第二军医大学学报》2017年03期

【摘要】：随着对肾癌发病机制的日渐了解,小分子靶向药物如舒尼替尼和索拉非尼等已经被广泛应用于临床,显著提高了肾癌患者的生存时间。然而,约有15%的进展期肾癌患者对靶向药物先天耐药,其余患者在接受舒尼替尼治疗6~15个月后也往往出现耐药和疾病进展,成为晚期肾癌治疗的瓶颈。因此,探索肾癌靶向耐药的生物学机制以及寻找预测靶向药物疗效的生物学标记物十分迫切。我们团队近期的研究发现了在肾癌靶向药物耐药过程中起关键作用的长链非编码RNA(lncRNA),相关研究成果发表在Cancer Cell、Nature Communications和Oncogene等国际知名期刊上。本文总结了我们团队关于肾癌靶向药物耐药研究的新成果,并对未来靶向药物耐药研究的方向和难点进行了探讨。
[Abstract]:With the increasing understanding of the pathogenesis of renal cell carcinoma, small molecular targeted drugs such as sunitinib and sorafenib have been widely used in clinical practice, significantly increasing the survival time of patients with renal cell carcinoma. However, about 15% of patients with advanced renal cell carcinoma are innate resistant to targeted drugs, and the others often develop drug resistance and disease progression after treatment with sulnitinib for 6 to 15 months, which has become the bottleneck in the treatment of advanced renal cell carcinoma. Therefore, it is very urgent to explore the biological mechanism of targeted drug resistance in renal cell carcinoma and to find biological markers to predict the efficacy of targeted drugs. Our team's recent research has identified long chain noncoding RNAs (LNRNAs) that play a key role in targeting drug resistance in renal cell carcinoma (RCC), and have been published in internationally recognized journals such as Cancer Cell Communications and Oncogene. In this paper, we summarized the new achievements of our team in the research of targeted drug resistance in renal cell carcinoma, and discussed the direction and difficulties of drug resistance research in the future.
【作者单位】：第二军医大学长征医院泌尿外科;南京大学附属金陵医院泌尿外科;
【基金】：国家自然科学基金(81572521) 上海市科委扬帆人才计划(16YF1403600)~~
【分类号】：R737.11

【相似文献】